Loading organizations...
§ Private Profile · Los Angeles, CA, USA
Biotech firm developing next-generation immune-modulating therapeutics for oncology, leveraging NK cells.
Based in Los Angeles, California, Fuse Biotherapeutics is a biotechnology company developing next-generation immune-modulating therapeutics designed specifically for oncology patients. The firm's proprietary medical platform leverages the inherent ability of natural killer cells to distinguish diseased tissues from healthy ones, integrating both innate and adaptive immunity to target tumors while sparing normal cellular structures. Operating with a lean team of fewer than ten employees, the enterprise supports its ongoing clinical research and early-stage platform development entirely through private venture capital backing. In November 2021, the organization successfully secured $9.5 million in an oversubscribed seed financing round led by Viva BioInnovator, alongside institutional investments from Sherpa Healthcare Partners, Ivy Venture Group, and Sirona Capital. Fuse Biotherapeutics was officially founded in 2021 by biomedical researchers and executives Paul Y. Song, Brian Rabinovich, Evren Alici, and Jeffrey Takimoto.
Fuse Biotherapeutics has raised $9.5M across 1 funding round.
Fuse Biotherapeutics has raised $9.5M in total across 1 funding round.
Fuse Biotherapeutics has raised $9.5M in total across 1 funding round.
Fuse Biotherapeutics's investors include GC&H Investments, Ivy Venture Group, Darren Cai, Sirona Capital.
Fuse Biotherapeutics has raised $9.5M across 1 funding round. Most recently, it raised $9.5M Seed in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 30, 2021 | $9.5M Seed | — | Gc&h Investments, IVY Venture Group, Darren CAI, Sirona Capital | Announced |